Pharmacological treatment options for osteoarthritis: focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert Meeting

• Main Authors: A. M. Lila, L. I. Alekseeva, A. R. Babaeva, I. Z. Gaydukova, G. Gandolini, E. V. Zonova, R. Capelli, A. E. Karateev, S. S. Kopenkin, N. A. Martusevich, O. B. Nesmeyanova, E. N. Otteva, F. Rannuе, T. A. Raskina, M. L. Sukhareva, E. A. Taskina, N. V. Chichasova, S. P. Yakupova
• Format: Article
• Language: Russian
• Published: IMA-PRESS LLC 2019-10-01
• Series: Современная ревматология
• Online Access: https://mrj.ima-press.net/mrj/article/view/973
• ISSN: 1996-7012; 2310-158X

The paper presents the results of the Osteoarthritis (OA) Expert Council held on September 8, 2019, which was attended by Russian and foreign specialists. The experts considered pharmacological treatment options for OA. The expert meeting resolution states that the treatment of patients with OA should be based on an individual assessment of the patient and on a modern evidence base of therapy efficacy.Treatment of patients with OA is based on the principles of evidence-based medicine that requires an integrated approach and the need of SYSADOAs prescription. Combined drugs with therapeutic dosages of chondroitin sulfate and glucosamine in the early stages of the disease are available as basic agents. The place of paracetamol in the anesthetic therapy algorithm in OA needs to be clarified. It is also noted that when choosing nonsteroidal anti-inflammatory drugs for OA treatment, it is important to take into account individual patient characteristics and the presence of comorbidities.